Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Dactinomycin

FDA-approved product (injectable, injection), marketed as Cosmegen, Dactinomycin.

Registered studies
50+
Lab records
1
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Dactinomycin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Kidney Wilms tumor
  • Neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Actinomycines
FDA pharmacologic class
Actinomycin FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli, K. pneumoniae and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA95.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli52.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae56.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis64.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • MRSA: measured active in 1 of 1 lab record
Open Dactinomycin in ChEMBL Registered studies below
Show the 1 laboratory record, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Dactinomycin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Combination Chemotherapy Alone or With Radiation Therapy in Treating Children With Kidney Cancer

    NCT00002611 · start 1995-07

    Registered record
    Registry ID
    NCT00002611
    Conditions
    Kidney Cancer
    Interventions
    dactinomycin; filgrastim; cyclophosphamide; doxorubicin hydrochloride; etoposide; vincristine sulfate; conventional surgery; radiation therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    1995-07
    Completion
    2003-08
    Enrolment
    3,031

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionKidney Cancer
    Interventiondactinomycin; filgrastim; cyclophosphamide; doxorubicin hydrochloride +4 more
    PhasePhase 3
    Registry statusCompleted

  • Surgery Followed by Chemotherapy in Treating Young Patients With Soft Tissue Sarcoma

    NCT00002898 · start 1995-01

    Registered record
    Registry ID
    NCT00002898
    Conditions
    Childhood Malignant Fibrous Histiocytoma of Bone; Sarcoma
    Interventions
    dactinomycin; carboplatin; cyclophosphamide; epirubicin hydrochloride; etoposide; ifosfamide; vincristine sulfate; adjuvant therapy; conventional surgery; neoadjuvant therapy; brachytherapy; radiation therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    1995-01
    Completion
    2009-12
    Enrolment
    400

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChildhood Malignant Fibrous Histiocytoma of Bone; Sarcoma
    Interventiondactinomycin; carboplatin; cyclophosphamide; epirubicin hydrochloride +8 more
    PhasePhase 3
    Registry statusCompleted

  • Chemotherapy Plus Surgery in Treating Children at Risk of or With Stage I Wilms' Tumor

    NCT00003804 · start 1993-07

    Registered record
    Registry ID
    NCT00003804
    Conditions
    Kidney Cancer
    Interventions
    dactinomycin; vincristine sulfate; conventional surgery
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    1993-07
    Completion
    Not recorded
    Enrolment
    350

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionKidney Cancer
    Interventiondactinomycin; vincristine sulfate; conventional surgery
    PhasePhase 3
    Registry statusUnknown

  • Combination Chemotherapy Plus Surgery and Radiation Therapy in Treating Patients With Ewing's Sarcoma

    NCT00002516 · start 1992-07

    Registered record
    Registry ID
    NCT00002516
    Conditions
    Sarcoma
    Interventions
    dactinomycin; cyclophosphamide; doxorubicin hydrochloride; etoposide; ifosfamide; mesna; vincristine sulfate; conventional surgery; low-LET cobalt-60 gamma ray therapy; low-LET photon therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    1992-07
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSarcoma
    Interventiondactinomycin; cyclophosphamide; doxorubicin hydrochloride; etoposide +6 more
    PhasePhase 3
    Registry statusUnknown

  • Combination Chemotherapy in Treating Children With Non-testicular Malignant Germ Cell Tumors

    NCT00002489 · start 1991-10

    Registered record
    Registry ID
    NCT00002489
    Conditions
    Extragonadal Germ Cell Tumor; Ovarian Cancer
    Interventions
    dactinomycin; filgrastim; carboplatin; cyclophosphamide; doxorubicin hydrochloride; etoposide; leucovorin calcium; methotrexate; vincristine sulfate; conventional surgery
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    1991-10
    Completion
    2002-06
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionExtragonadal Germ Cell Tumor; Ovarian Cancer
    Interventiondactinomycin; filgrastim; carboplatin; cyclophosphamide +6 more
    PhasePhase 2
    Registry statusCompleted